Overview

Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C

Status:
Completed
Trial end date:
2020-09-16
Target enrollment:
Participant gender:
Summary
Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
AbbVie
Treatments:
Ribavirin